David Toro Tobon
@DavidToroT
Endocrinologist and Assistant Professor @MayoClinic, Internist @gtown_medres, MD @UniversidadCES. Views are my own. He/him
Hoping to inspire mentors and mentees with this collaborative work! @MayoClinicEndo @DavidToroT Mentorship in endocrinology training: a cross-sectional study of the U... sciencedirect.com/science/articl…
How well can we predict which patients with #GravesDisease will recur after remission? Read the March issue review by Joris Ospinga of a new paper from authors at #MayoClinic. ow.ly/Hbzk50Vyqn5 #medtwitter #endotwitter #hyperthyroidism @TheAACE @GDATF
Our latest review unpacks the evolving understanding, diagnostic dilemmas & clinical approach to Bilateral Adrenal Nodules With MACS 📚 @IrinaBancos @leili_rahimi @ShobanaAthi @TheAACE sciencedirect.com/science/articl…
Take a deep dive into the signature annual meeting of endocrinology and hormone research and make the most of your time at ENDO. Watch Society members, @Karavitaki_Niki; @DavidToroT; and @theophilustett2: bit.ly/4kH9b51 #ENDO2025 #endocrinology
Honored to have shared insights on Artificial Intelligence for Thyroid health and the risk of thyroid cancer with GLP-1 receptor agonists at the Thyroid Summit 2025! Great discussions with our Dominican Republic colleagues
Prednisone therapy (vs hydrocortisone) is associated with better quality of life in patients with #Cushing syndrome and #MACS post surgery. @MayoClinicEndo @BancosAdrenaLab @RSandooja @jasminesaini64 pubmed.ncbi.nlm.nih.gov/40317190/
ICMYI Dr. Toro Tobon broke down GLP-1 receptor agonists & thyroid cancer risk in our latest #TIROxMDS session with Dr. Mechanick. Catch the recording 👉 youtu.be/3N9UmcDxUJg?ut… #GLP1
NEW publication ALERT! ‼️ @IrinaBancos @jasminesaini64 @RaulGreggMD @MayoClinicEndo Impact of hydrocortisone versus prednisone therapy on post-surgical recovery in patients with endogenous hypercortisolism: a prospective cohort study academic.oup.com/ejendo/article…
Thank you @TheAACE for highlighting our work. Our study 🔍 introduces a predictive model for Graves' disease recurrence after antithyroid therapy 💊, featuring a nomogram for bedside clinical use. 🏥 Check out this thread: x.com/o_kawkgi/statu…
The authors developed a model incorporating risks of hyperthyroidism reoccurrence after ATD discontinuation, smoking status, antithyroid drug treatment duration, and sex to predict Graves' disease recurrence. Read more in #EndocrinePractice: endocrinepractice.org/article/S1530-… @vtangpricha…
This week we lost a pioneer in medicine. Dr. Steven A. Smith was on staff at #MayoEndo from 1993 to 2020. From re-imagining diabetes practices to directing the Patient Education Center for 18 years, Dr. Smith exemplified @MayoClinic values of humility and compassionate care.